Other · developed by Sol-Gel Technologies
DER 45 EV is a topically applied agent studied for rosacea of the face, applied to the skin over 12 weeks.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00940992 | Phase 2 | Rosacea | Completed | SLGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Rosacea
Updated Nov 1, 2026. Something wrong or missing? Report it on the SLGL page.
See SLGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SLGL catalysts and pipeline →